Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment. The aim is to evaluate the bone marrow protective effect of trilaciclib before docetaxel chemotherapy for locally advanced or metastatic NSCLC.

Trial Details

NCT ID

NCT06929936

Phase

PHASE2

Sponsor

The First Affiliated Hospital of Xiamen University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Trilaciclib combined with Docetaxel

Locations (sample)

Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

Patients must meet all of the following inclusion criteria to be included in this study:
Age ≥ 18 years old, regardless of gender;
Patients with stage IV NSCLC who have failed at least one line of standard treatment regimen:
A. Patients with negative driver genes must have received first line standard treatment (chemotherapy combined with immunotherapy).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →